CORPORATE OVERVIEW

November 2022

DISCLAIMER

This presentation has been prepared by the Company. “Presentation” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed during the meeting. This presentation does not constitute or form part of any offer to sell or issue, or invitation to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities of the Company or any of its subsidiaries (together the “Group”) or in any other entity, nor shall this presentation or any part of it, or the fact of its presentation, form the basis of, or be relied on in connection with, any contract or investment activity nor does it constitute a recommendation regarding the securities of the Group. Past performance, including the price at which the Company’s securities have been bought or sold in the past and the past yield on the Company’s securities, cannot be relied on as a guide to future performance. Nothing herein should be construed as financial, legal, tax, accounting, actuarial or other specialist advice and persons needing advice should consult an independent financial adviser or independent legal counsel. Neither this presentation nor any information contained in this presentation should be transmitted into, distributed in or otherwise made available in whole or in part by the recipients of the presentation to any other person in any jurisdiction which prohibits or restricts the same except in compliance with or as permitted by law or regulation. Recipients of this presentation are required to inform themselves of and comply with all restrictions or prohibitions in such jurisdictions.

Accordingly, by requesting to receive and reviewing this document you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you. No responsibility is accepted by and, to the fullest extent permitted by law, the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents expressly disclaim any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, as to the accuracy, fairness, reliability or completeness of the information contained herein or discussed verbally or as to the reasonableness of any assumptions on which any of the same is based or the use of any of the same or for any errors, omissions or misstatements in or from this presentation. No representations or warranties, express or implied, are given by the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents as to the accuracy, reliability or completeness of this presentation or any other written or oral information which has been or may be made available. Accordingly, no such person will be liable for any direct, indirect or consequential loss or damage suffered by any person resulting from the use of the information contained herein, or for any opinions expressed by any such person, or any errors, omissions or misstatements made by any of them. No duty of care is owed or will be deemed to be owed to any person in relation to the presentation. No reliance whatsoever may be placed on the presentation for any purpose. By accepting this presentation, you agree to use and maintain any such information in accordance with your contractual obligations and applicable laws, including all applicable securities laws. The information contained in this presentation has not been independently verified.

The Amryt logo, Myalept®, Myalepta®, Juxtapid®, Lojuxta®, Filsuvez® and Mycapssa® and other trademarks or service marks of Amryt appearing in this presentation are the property of Amryt. This presentation includes trademarks, tradenames and service marks, certain of which belong to us and others that are the property of other organizations. Solely for convenience, trademarks, tradenames and service marks referred to in this presentation appear without the ®, TM and SM symbols, but the absence of those symbols is not intended to indicate, in any way, that we will not assert our rights or that the applicable owner will not assert its rights to these trademarks, tradenames and service marks to the fullest extent under applicable law. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties. Filsuvez® (Oleogel-S10/birch triterpenes/formerly known as AP101) is currently an investigational product and has not received regulatory approval by the FDA or EMA. Elements of this presentation only apply in the event that Filsuvez® is approved by the appropriate regulatory authorities. Mycapssa® has been approved by the FDA for the long-term maintenance treatment in patients with acromegaly who have responded to and tolerated treatment with octreotide or lanreotide but remains an investigational drug outside the US and for other indications. This presentation is intended only for communications with investors.

FORWARD-LOOKING STATEMENTS

This presentation may contain forward-looking statements containing the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this communication are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, and actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond each of Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions.

The delivery of this presentation shall not give rise to any implication that there have been no changes to the information and opinions contained in this presentation since the time specified. Subject to obligations under the Securities and Exchange Commission (“SEC”) (as amended from time to time), none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes to publicly update or revise any such information or opinions, including without limitation, any forward-looking statement or any other statements contained in this presentation, whether as a result of new information, future events or otherwise. In giving this presentation none of the Company, the Group, their affiliates and advisers and their respective directors, officers, partners, representatives, employees and agents, undertakes any obligation to provide the recipient with access to any additional information or to update any additional information or to correct any inaccuracies in any such information which may become apparent. Certain industry and market data contained in this presentation has been obtained from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies or surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry, scientific and market data contained in this presentation comes from the Company’s own internal case studies, research and estimates based on the knowledge and experience of the Company’s management in the market in which it operates. While the Company believes that such research, estimates and results from its case studies are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness unless otherwise stated and are subject to change without notice. Risks and uncertainties affecting the Company are outlined further in the Company SEC filings.

AMRYT CORPORATE OVERVIEW

GLOBAL, COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO ACQUIRING, DEVELOPING AND COMMERCIALIZING NOVEL TREATMENTS FOR RARE DISEASES

- **Four growing commercial products: metreleptin, Mycapssa®, Filsuvez® and lomitapide**
- **Global commercial infrastructure, financial flexibility & experienced team in place to drive product growth**
- **EBITDA positive driving strong operating cash flows**
- **Significant development pipeline with multiple near and medium-term growth drivers**
- **Track record of successful acquisition, integration, performance and growth**
- **NASDAQ (AMYT); global HQ in Dublin, Ireland; US HQ in Boston MA**

CONSISTENT PERFORMANCE AND GROWTH

Q3 2022 AND RECENT HIGHLIGHTS

8.2% YoY revenue growth in Q3 2022 to $61.1M (Q3 2021: $56.5M); 12.5% YoY revenue growth on a constant currency basis

Generated EBITDA** of $12.5M in Q3 2022 - 11th consecutive quarter of positive EBITDA generation

Operating cash flows of $14.3M for Q3 2022

Cash of $83.4M at September 30, 2022

Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY

Pathway agreed with FDA to initiate a Phase 3 study for NET - expected Q1 2023

Filsuvez® European launch progressing well

Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4

Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth



* Unaudited combined revenues for 2019 represent the pro forma combined unaudited revenues of the Company assuming the acquisition by Amryt of Aegerion happened on 1 January 2019. These amounts (i) exclude revenues from sales to end-users in Japan, due to the out-licencing of lomitapide (Juxtapid®) to Recordati, which occurred in February 2019, (ii) exclude up-front payments from Recordati in 2019, and (iii) include a 22.5% royalty on Japanese sales of lomitapide (Juxtapid®) from 1 January 2019, as if the Recordati agreement were in place from that date. ** See non-GAAP/IFRS reconciliation

AMRYT PHARMA

GLOBAL INFRASTRUCTURE

INFRASTRUCTURE IN PLACE TO DRIVE GLOBAL GROWTH



INDUSTRY LEADERS IN RARE DISEASES

DR JOE WILEY
CEO

SOFINNOVA VENTURES
astellas

RORY NEALON
COO/CFO

AIB
Trinity Biotech

STEPHEN JOYCE
Head of Marketing, Head of APAC

Fujisawa
astellas

DR GERRY GILLIGAN
VP Manufacturing Supply Chain

LEO
Bristol Myers Squibb

DR TRACY CUNNINGHAM
Chief Medical Officer

SANOFI
gsk
AstraZeneca

FINN DOYLE
Head of Commercial Strategy

NOVARTIS
abbvie

JOHN MC EVOY
General Counsel

ARTHUR COX
HERBERT SMITH FREEHILLS

DR HELEN PHILLIPS
Head of Medical Affairs

Aegerion Pharmaceuticals
Eisai
gsk
AstraZeneca

KIERAN ROONEY
Head of Business Development

amakem THERAPEUTICS
NORGINE
pwc

JULIE EASTWOOD
Head of Human Resources

Totalmobile
TRICASTLE

SHEILA FRAME
President Americas

AstraZeneca
NOVARTIS
Bristol Myers Squibb

JORDI CASALS
President of EMEA

GRIFOLS
ALEXION
Otsuka

ELIZABETH JOBES
Chief Compliance Officer

AUXILIUM
Spark THERAPEUTICS

AMRYT PHARMA

GROWING COMMERCIAL PORTFOLIO & ENHANCED COMBINED DEVELOPMENT PIPELINE

EARLY AND LATE-STAGE PIPELINE WITH MULTIPLE VALUE INFLECTION POINTS

PROGRAM	INDICATION	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	MARKETED	UPCOMING MILESTONES
Metreleptin (Myalept® / Myalepta®)	GL						
	PL(1)					EU	
					US		Phase 3 study initiated Q4 2021
Lomitapide (Juxtapid® / Lojuxta®)	HoFH (adults)						
	HoFH (Pediatrics)(2)					EU	Data expected Q4 2022
Mycapssa®	Acromegaly						Launched Sep ’20 in US. CHMP positive opinion Q3 2022. EC approval expected Q4 2022
	Neuroendocrine tumors (NET)(3)						Phase 3 initiation anticipated Q1 2023
Oleogel-S10 (Filsuvez®)	EB (DEB / JEB)					EU	European Commission approval June 2022 Great Britain approval September 2022
					US		
	Radiation-Induced Dermatitis						Investigator- initiated study Q4 2021
AP103	EB (DEB)						Clinical development planned 2024

Definitions: Dystrophic EB (“DEB”); Junctional EB (“JEB”)
(1) Global Phase 3 study to support US label expansion for metreleptin in the treatment of partial lipodystrophy (PL).
(2) We are conducting a Phase 3 study of homozygous familial hypercholesterolemia ("HoFH") in children and adolescents in Europe, the Middle East and Africa ("EMEA") as part of our European Medicines Agency (“EMA”) pediatric investigation plan (PIP) commitment.
(3) 505(b)(2) pathway Phase 2 not required, Phase 3 initiation anticipated in Q1 2023 for the treatment of carcinoid symptoms in NET.

AMRYT PHARMA

METRELEPTIN - LIPODYSTROPHY MARKET OVERVIEW

Metreleptin is approved in the US (under the trade name Myalept®) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta®) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control

$530M	Global LD market
$280M	455 eligible LD patients in the US*
$180M	910 eligible LD patients in EMEA*
$70M	475 eligible LD patients* in other markets**

Lipodystrophy is a chronic condition associated with low leptin levels as a result of the loss of adipose tissue. Leptin is an important hormone for energy homeostasis and metabolic function. Low leptin can result in metabolic chaos typically resulting in:

Fatty liver

Insatiable appetite

Chronic fatigue

Diabetes

Pancreatitis

Organ damage

Reduced life expectancy

* Prevalence – 1.0 per million GL – 3.0 per million PL, discounted to 1.0 per million for severe cases.
** Includes key markets in which Amryt operates: Brazil, Argentina, Colombia and Canada.

KEY BARRIERS TO DEVELOPMENT OF A METRELEPTIN BIOSIMILAR

~100+

- Reference biologics with **more attractive revenue opportunities** than metreleptin (peak global revenues above $200M - $500M)

- Orphan Drug Exclusivity in PL would further **reduce the mid-term opportunity for a biosimilar** with a 'skinny' label in GL

$100 - 300MM

- **High biosimilar development cost** and long timeline
  - Total development costs estimated to be in excess of $100M[1]
  - Development time estimated at 5 to 9 years[1]

- 84% of all FDA approved biosimilars (32 out of 38) competed comparative Phase 3 studies[2]
- FDA and EMA similarly require comparative studies where there is uncertainty about whether there are clinically meaningful differences with the reference product[3]
- Metreleptin price is a major cost driver as the sponsor must purchase the reference drug for a comparative trial
- REMS program with an ETASU
- Ultra-rare disease assets – small number of patients[4]

Source: Health Advances analysis

1. Pfizer Biosimilars (accessed 9/16/22), McKinsey 2022 Three Imperatives for R&D in Biosimilars
2. Moore et al 2021 JAMA Intern Med
3. FDA 2015 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. EMA 2014 Revised Overarching Guideline on Biosimilar
4. Hoss A. Dowlat (2016) The opportunities and challenges of biosimilar orphans, Expert Opinion on Orphan Drugs, https://doi.org/10.1517/21678707.2016.1171142

AMRYT PHARMA

LOMITAPIDE - HOFH MARKET OVERVIEW

Lomitapide is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal treatments for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid®) and in the EU, Israel and Brazil (under the trade name Lojuxta®).

$250M	Estimated global market for HoFH
$110M	250 eligible HoFH patients in US*
$100M	600 eligible patients in EMEA*
$40M	255 eligible HoFH patients* in other markets**

HoFH is a potentially life-threatening disorder that impairs the body's ability to remove LDL "bad" cholesterol from the blood resulting in:

high LDL cholesterol levels

blocking of arterial blood vessels

high risk of cardiovascular events

reduced life expectancy

* Includes Pediatric HoFH market opportunity. Prevalence – 3 per million EU, America, Australia; 6 per million – due to consanguinity, e.g. Middle East, Turkey and founder effects, e.g. Canada. 50% diagnosis rate based on phenotypic presentation of LDL-C levels. Approx. 50% eligible population after PCSK9 inhibitors address a portion of the unmet medical need. Excludes FCS.
** Includes key markets in which Amryt operates: Brazil, Argentina, Colombia and Canada.

AMRYT PHARMA

MYCAPSSA® - ACROMEGALY - MARKET OVERVIEW

Mycapssa® is the first and only FDA-approved oral somatostatin analog (SSA) for appropriate patients with acromegaly, providing effective and consistent biochemical control while reducing the treatment burden associated with injectable therapies.

Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments

Injections present significant challenges to patients*

$800M	Global market**
$400M	US market opportunity**
$400M	Ex-US market opportunity**

Acromegaly is a rare disease most often caused by a benign pituitary tumor and characterized by an excess of growth hormone and insulin-like growth factor-1 hormone. Treatment options include surgery, medication and radiation or a combination of these.

If untreated, may cause:


Altered facial appearance


Enlargement of the hands and feet


Type 2 diabetes


Intense headaches


Joint pain


Respiratory disorders


Cardiac disease


Cerebrovascular disease

*Strasburger, et al. Patient reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly. Eur J Endocrinology. 2016 Mar; 174(3):355-62
**Management estimates based on 2019 available market data.

MYCAPSSA® - NEUROENDOCRINE TUMOR (NET) - MARKET OVERVIEW

Amryt is advancing Mycapssa® into late-stage clinical development for the treatment of neuroendocrine tumors (NET) patients with carcinoid symptoms

Current standard of care is octreotide LAR and lanreotide depot injections

Potential addressable patient population on SSAs estimated at ~24,000 in the US**

$1.9B	Global market***
$1.0B	US market opportunity***
$0.9B	Ex-US market opportunity***

NETs are abnormal growths of neuroendocrine cells occurring throughout the body (most common in GI tract). NETs can metastasize and produce hormones that cause significant symptoms ("carcinoid syndrome" which includes diarrhea and flushing episodes)*. NET Symptoms Include:

Diarrhea & Constipation

Flushing

Fatigue

Anxiety & Depression

GI Tract Malignancies

Pancreatic Malignancies

Lung Malignancies

*Hauso et al, Cancer, 2008; Cancer Research UK.
**National Cancer Institute SEER Database; Halperin et al. 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066284/
***Based on management estimates.

MYCAPSSA® - DEVELOPMENT AND REGULATORY TIMELINE FOR NET PROGRAM

Q3 2021 - FDA agreed that a single positive Phase 3 study would be sufficient for approval in neuroendocrine tumors (NET) patients with carcinoid symptoms, consistent with the 505(b)(2) regulatory pathway

The Agency recommended that the primary endpoint in a Phase 3 study should demonstrate that patients are able to maintain the baseline level of “stability” during treatment with Mycapssa®

Q1 2022	Q2 2022	Q4 2022	H1 2023	2024
PK data enables Amryt to proceed with planned Phase 3 study design	Comprehensive written response received from FDA following Type C meeting which strengthens program	Patient observational study	Phase 3 initiation anticipated	Top-line Phase 3 data anticipated

FILSUVEZ® - FIRST APPROVED THERAPY FOR EB

European Commission and GB have approved Filsuvez® for the treatment of dystrophic and junctional EB in patients 6 months and older

Phase 3 EASE study investigating Filsuvez® was the largest ever global trial and first ever positive readout in EB

Primary endpoint was met demonstrating 44% increase in target wound closure with Filsuvez® versus control gel

Filsuvez® was shown to be well tolerated with a reassuring safety profile

> $1.0B Estimated global EB market*

EB is a rare and devastating group of hereditary disorders of the skin, mucous membranes, and internal epithelial linings characterized by extreme skin fragility and blister development. Patients with severe forms of EB suffer from:

chronic wounds

recurrent blistering

scarring

intolerable pain

limited mobility

high risk of infection

high risk of cancer

risk of early death

*Based on management estimates

AMRYT PHARMA

FILSUVEZ® - EUROPEAN LAUNCH ON TRACK

POTENTIAL TO LEVERAGE EU APPROVAL ACROSS OTHER JURISDICTIONS

EU approval (Jun)
GB Approval (Sep)

Q2/Q3 2022

Germany first shipments

Q3 2022

Phase 1 (European 5) reimbursement submissions

by Q1 2023

Phase 1 reimbursement approvals expected

by Q1 2024

Phase 2 reimbursement approvals expected

2024-25

SMALL NUMBER OF CENTERS TREATING MAJORITY OF EB PATIENTS IN EUROPE



United Kingdom

- St Thomas'
- Great Ormond Street
- Birmingham

Debra UK
Cure EB

France

- Necker
- St. Louis
- Toulouse
- Nice
- Bordeaux

Debra France

Germany + Austria

- Freiburg
- Hannover
- Berlin
- Kiel
- Cologne
- Erlangen
- Munich
- Salzburg

Debra Germany
Eb Haus

Spain

- Hospital La Paz
- Hospital Sant Joan de Déu

Debra Spain

Italy

- Rome
- Milan
- Bari
- Padova
- Bologna
- Modena

Debra Italy

Source: Amryt Management

AP103 - BUILDING AN EB FRANCHISE - GENE THERAPY PLATFORM

- Novel polymer-based topical gene therapy delivery platform
- AP103, our first product candidate utilizing this platform, is being studied for DEB
- Granted Orphan Drug Designation by FDA and EMA in 2020
- Potential use for the treatment of other genetic diseases

From Polyplex to Gene Expression



* Highly Branched Poly β-Amino Ester

AMRYT PHARMA

AP103 - PROOF OF CONCEPT IN A PRE-CLINICAL EB MODEL



Phase 1/2a clinical trial to begin in 2024



AMRYT PHARMA

CONSISTENT FINANCIAL PERFORMANCE AND GROWTH

BUILDING A GLOBAL LEADER IN RARE DISEASES









*See Appendix: non-GAAP/IFRS reconciliation
Note: All quarterly financials are unaudited

AMRYT PHARMA

STRONG FINANCIALS

BUILDING A GLOBAL LEADER IN RARE DISEASES

EBITDA AND CASH

$41.9M EBITDA* in FY 2021 excl. restructuring costs

$12.5M EBITDA* in Q3 2022 excl. restructuring costs

Cash $83.4M** at June 30, 2022

REVENUE

FY 2021 revenues $222.5M

FY 2022 revenue guidance $260M - $270M representing 17-21% growth YoY

$125M CONVERTIBLE DEBT FACILITY

5.5 year bullet, Apr 2025

Unsecured

Coupon: 5% cash

Convertible price: $12.93 per ADS

$125M TERM DEBT FACILITY ($105M DRAWN)

$85M term loan - SOFR**+6.75%

$40M RCF ($20M drawn) - SOFR** +4.00%

5 year bullet, Feb 2027 (refinanced Feb ‘22)

Secured

*Unaudited see Appendix: non-GAAP/IFRS reconciliation
**SOFR, subject to a floor of 0.90%

CONTACT & CORPORATE INFORMATION

BUILDING A GLOBAL LEADER IN RARE DISEASES

AMRYT CONTACT	
Dr Joe Wiley CEO	joe.wiley@amrytpharma.com
Rory Nealon CFO/COO	rory.nealon@amrytpharma.com
Kieran Rooney BD	kieran.rooney@amrytpharma.com
Investor Relations	ir@amrytpharma.com

AMRYT COVERAGE	
Mani Foroohar SVB Leerink	mani.foroohar@svbleerink.com + 1 212 277 6089
Brandon Folkes Cantor Fitzgerald	brandon.folkes@cantor.com +1 212 294 8081
Edward Nash Canaccord Genuity	enash@cgf.com +1 212 389 8128
Max Herrmann Stifel Nicolaus	max.herrmann@stifel.com +44 207 710 7606
Naz Rahman Maxim Group	nrahman@maximgrp.com + 1 212 895 3642
Catherine Novack Jones Research	cnovack@jonestrading.com + 1 646 454 7268
Douglas Tsao H.C. Wainwright	dtsao@hcwresearch.com + 1 212 916 3698
Brian White Shore Capital	brian.white@shorecap.co.uk +44 207 079 1670

LISTING PARTICULARS	NASDAQ
TICKER	AMYT

AMRYT - A GLOBAL LEADER IN RARE DISEASES



Revenue generating commercial portfolio with four approved and growing products, driving positive EBITDA

Track record of successful acquisition, integration, performance and growth

Significant development pipeline with multiple near and medium-term growth drivers

Global commercial infrastructure, financial flexibility and experienced team in place to drive product growth

APPENDIX

IFRS AND NON-GAAP ADJUSTED RESULTS – Q3 2022 EBITDA

US$M	Q3 2022 (unaudited)	Q3 2022 Non-cash Items[1]	Q3 2022 Non-GAAP Adjusted
Revenue	**61.1**	**-**	**61.1**
Gross profit	**27.4**	**19.7**	**47.1**
R&D expenses	(8.0)	-	(8.0)
SG&A expenses	(27.0)	0.4	(26.6)
Share based compensation expenses	(2.9)	2.9	-
Operating (loss) / profit before finance expense	**(10.5)**	**23.0**	**12.5[2]**

1. Non-cash items include amortisation of the acquired metreleptin, lomitapide, Mycapssa® and Filsuvez® intangible assets ($16.6M), amortisation of the inventory fair value step-up related to the acquisition of Chiasma, Inc. ($3.1M), depreciation and amortisation ($0.4M) and share based compensation expenses ($2.9M).
2. EBITDA is earnings before interest, tax, depreciation, amortisation and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

IFRS AND NON-GAAP ADJUSTED RESULTS - FY 2021 EBITDA[2]

US$M	FY 2021 (unaudited)	FY 2021 Non-cash adjustments[1]	FY 2021 Non-GAAP Adjusted
Revenue	**222.5**	**-**	**222.5**
Cost of sales	(106.1)	53.4	(52.7)
Gross profit	**116.4**	**53.4**	**169.8**
R&D expenses	(37.7)	-	(37.7)
SG&A expenses	(92.0)	1.8	(90.2)
Acquisition & severance related costs	(16.9)	-	(16.9)
Share based compensation expenses	(8.3)	8.3	-
Impairment charge	(32.6)	32.6	-
Operating (loss) / profit before finance expense	**(71.2)**	**96.1**	**25.0[2]**
Operating (loss) / profit before finance expense and restructuring and severance related costs (EBITDA[1])	**(54.3)**	**96.1**	**41.9[2]**

1. Non-cash items for FY21 include amortisation of the acquired metreleptin, lomitapide and Mycapssa® intangible assets ($49.0M), amortisation of the inventory fair value step-up related to the acquisition of Chiasma and Aegerion ($4.4M), depreciation and amortisation ($1.8M), impairment charge ($32.6M) and share based compensation expenses ($8.3M).
2. EBITDA, as applied in the above table, is defined as earnings before interest, tax, depreciation, amortisation, impairment, restructuring and severance related costs and share based compensation expenses. To supplement Amryt's financial results presented in accordance with IFRS generally accepted accounting principles, the Company uses EBITDA as a key measure of company performance as the Company believes that this measure is most reflective of the operational profitability or loss of the Company and provides management and investors with useful supplementary information which can enhance their ability to evaluate the operating performance of the business. EBITDA, as measured by the Company, is not meant to be considered in isolation or as a substitute to operating profit / loss attributable to Amryt and should be read in conjunction with the Company's condensed consolidated financial statements prepared in accordance with IFRS.

MYALEPT® (US) REGULATORY EXCLUSIVITY / PATENT TIMELINE ASSUMES LOE JULY 2027



* A PTE of 1,445 days was applied to the '254 patent, thus extending patent protection to July 17, 2027.

MYALEPTA® (EX-US) REGULATORY EXCLUSIVITY / PATENT TIMELINE ASSUMES LOE JULY 2028 WITH POTENTIAL 2-YEAR EXTENSION



AMRYT PHARMA

MYCAPSSA® - US EXCLUSIVITY TIMELINE

Regulatory Exclusivity



Patent Exclusivity

Patent Summary:

- 3 formulation and 1 acromegaly use patents expire Sept 2029
- 4 acromegaly use patents (acromegaly) expire February 2036
- 1 octreotide method of use patent expiring December 2040
- 1 pending application covers NET/VIP use est. expiration January 2037

AMRYT PHARMA

MYCAPSSA®- EUROPEAN EXCLUSIVITY TIMELINE

Regulatory Exclusivity



Patent Exclusivity

Regulatory Summary:
- Orphan exclusivity prevents generic entry Q2 2032

Patent Summary:
- Composition patent expires Sept 2029
- Acromegaly Use Application, if allowed would expire Feb 2036

Label expansion to include NET:
- Orphan exclusivity would NOT prevent approval of NET product

Assumptions:
Product approval Q4 2022

AMRYT PHARMA

JUXTAPID® US REGULATORY EXCLUSIVITY / PATENT TIMELINE

Approved December 2012



*Patent Term Adjustment of 895 days was awarded due to Patent Office delays, extending term to 8/19/2027

AMRYT PHARMA

LOJUXTA® EU REGULATORY EXCLUSIVITY/PATENT TIMELINE



AMRYT PHARMA

FILSUVEZ® ANTICIPATED EXCLUSIVITY TIMELINE IN US



Granted Patents



AMRYT PHARMA

FILSUVEZ® ANTICIPATED EXCLUSIVITY IN EUROPE AND JAPAN

Regulatory



Granted Patents

EP 1758555 JP 4468987	Oleogel, method of producing oleogel SPCs for some EP countries
EP 2504012 JP 6017959	Oleogel for use in wound healing
JP 6263239	Oleogel for use in treating EB

Pending Claims

Future IP – Pending Method of Use and Commercial Oleogel Claims

AMRYT PHARMA

AP103 REGULATORY AND PATENT EXCLUSIVITIES



Patent Protection

Existing IP — **Potential PTE/SPCs**

Future IP

- Physical properties / improvements
- QC/CMC
- Formulation
- Clinical findings/indications/patient populations

AMRYT PHARMA